NCT05926440View on ClinicalTrials.gov

Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

August 17, 2023

Primary Completion Date

August 17, 2023

Study Completion Date

August 17, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

SCB-2023 vaccine (trivalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

BIOLOGICAL

SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

SCB-2019 (monovalent), a recombinant SARS-CoV-2 trimeric S-protein subunit vaccine for COVID-19; intramuscular injection

Trial Locations (3)

Unknown

Health Index Multispecialty Clinic, Manila

Manila Doctors Hospital, Manila

Tropical Disease Foundation, Putatan

Sponsors
All Listed Sponsors
lead

Clover Biopharmaceuticals AUS Pty

INDUSTRY